重新审视顽固性高血压
Rethinking Resistant Hypertension.
作者信息
Bourque Gabrielle, Hiremath Swapnil
机构信息
Department of Medicine, University of Ottawa, Ottawa, ON K1H 7W9, Canada.
出版信息
J Clin Med. 2022 Mar 7;11(5):1455. doi: 10.3390/jcm11051455.
Abstract
Resistant hypertension is common and known to be a risk factor for cardiovascular events, including stroke, myocardial infarction, heart failure, and cardiovascular mortality, as well as adverse renal events, including chronic kidney disease and end-stage kidney disease. This review will discuss the definition of resistant hypertension as well as the most recent evidence regarding its diagnosis, evaluation, and management. The issue of medication non-adherence and its association with apparent treatment-resistant hypertension will be addressed. Non-pharmacological interventions for the treatment of resistant hypertension will be reviewed. Particular emphasis will be placed on pharmacological interventions, highlighting the role of mineralocorticoid receptor antagonists and sodium-glucose cotransporter-2 inhibitors and device therapy, including renal denervation, baroreceptor activation or modulation, and central arteriovenous fistula creation.
摘要
难治性高血压很常见，并且已知是心血管事件的危险因素，包括中风、心肌梗死、心力衰竭和心血管死亡，以及不良肾脏事件，包括慢性肾脏病和终末期肾病。本综述将讨论难治性高血压的定义以及有关其诊断、评估和管理的最新证据。将探讨药物治疗依从性问题及其与明显治疗抵抗性高血压的关联。将回顾难治性高血压治疗的非药物干预措施。将特别强调药物干预，突出盐皮质激素受体拮抗剂和钠-葡萄糖协同转运蛋白2抑制剂的作用以及器械治疗，包括肾去神经支配、压力感受器激活或调节以及建立中心动静脉瘘。
相似文献
1
Rethinking Resistant Hypertension.重新审视顽固性高血压
J Clin Med. 2022 Mar 7;11(5):1455. doi: 10.3390/jcm11051455.
2
Resistant Hypertension in People With CKD: A Review.慢性肾脏病患者的耐药性高血压：综述。
Am J Kidney Dis. 2021 Jan;77(1):110-121. doi: 10.1053/j.ajkd.2020.04.017. Epub 2020 Jul 23.
3
New approaches in the treatment of hypertension.高血压治疗的新方法。
Circ Res. 2015 Mar 13;116(6):1074-95. doi: 10.1161/CIRCRESAHA.116.303603.
4
Treating resistant hypertension: role of renal denervation.治疗顽固性高血压：肾去神经支配的作用
Integr Blood Press Control. 2013 Sep 11;6:119-28. doi: 10.2147/IBPC.S33958.
5
Renal Dysfunction Induced by Kidney-Specific Gene Deletion of as a Primary Cause of Salt-Dependent Hypertension.肾脏特异性基因敲除 导致的肾功能障碍是盐依赖性高血压的主要原因。
Hypertension. 2017 Jul;70(1):111-118. doi: 10.1161/HYPERTENSIONAHA.116.08966. Epub 2017 May 30.
6
Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).抗高血压和降脂治疗预防心脏病发作试验（ALLHAT）：治疗抵抗性高血压与心血管疾病和终末期肾病的发病率。
Hypertension. 2014 Nov;64(5):1012-21. doi: 10.1161/HYPERTENSIONAHA.114.03850. Epub 2014 Aug 4.
7
Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved.钠-葡萄糖协同转运蛋白2抑制剂和盐皮质激素受体拮抗剂对慢性肾脏病的心血管保护作用：一项里程碑式的成果。
Hypertension. 2021 May 5;77(5):1442-1455. doi: 10.1161/HYPERTENSIONAHA.121.17005. Epub 2021 Mar 29.
8
Diagnosis and management of resistant hypertension: state of the art.耐药性高血压的诊断和治疗：最新进展。
Nat Rev Nephrol. 2018 Jul;14(7):428-441. doi: 10.1038/s41581-018-0006-6.
9
[Resistant hypertension].[顽固性高血压]
Wiad Lek. 2017;70(6 pt 2):1209-1214.
10
Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.钠-葡萄糖共转运蛋白 2 抑制剂和非甾体类盐皮质激素受体拮抗剂：在肾素-血管紧张素系统阻断之外开创肾脏保护的新时代。
Nephrology (Carlton). 2021 Nov;26(11):858-871. doi: 10.1111/nep.13917. Epub 2021 Jul 6.
引用本文的文献
1
The antihypertensive efficacy of a quadruple single-pill combination in patients with resistant hypertension: study protocol for a randomized, open-label, crossover trial.四联单片复方制剂治疗顽固性高血压患者的降压疗效：一项随机、开放标签、交叉试验的研究方案
Trials. 2025 Jan 20;26(1):22. doi: 10.1186/s13063-025-08719-8.
2
Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review.高血压与基于器械的顽固性高血压治疗：最新综述
Cureus. 2024 Aug 6;16(8):e66304. doi: 10.7759/cureus.66304. eCollection 2024 Aug.
3
Approaches in Managing Resistant Hypertension: A Review.难治性高血压的管理方法：综述
Cureus. 2024 Apr 8;16(4):e57804. doi: 10.7759/cureus.57804. eCollection 2024 Apr.
4
Zinc deficiency induces hypertension by paradoxically amplifying salt sensitivity under high salt intake in mice.缺锌通过在高盐摄入下反常地放大盐敏感性而导致高血压。
Clin Exp Nephrol. 2024 Aug;28(8):728-739. doi: 10.1007/s10157-024-02478-7. Epub 2024 Apr 6.
5
When blood pressure refuses to budge: exploring the complexity of resistant hypertension.当血压顽固不降时：探索顽固性高血压的复杂性。
Front Cardiovasc Med. 2023 Jun 21;10:1211199. doi: 10.3389/fcvm.2023.1211199. eCollection 2023.
6
A Need for Improvement in the Definition of Resistant Arterial Hypertension.需要改进耐药性高血压的定义。
Medicina (Kaunas). 2023 Apr 20;59(4):803. doi: 10.3390/medicina59040803.
7
Sustained Activation of CLR/RAMP Receptors by Gel-Forming Agonists.凝胶形成激动剂对 CLR/RAMP 受体的持续激活。
Int J Mol Sci. 2022 Nov 2;23(21):13408. doi: 10.3390/ijms232113408.
本文引用的文献
1
Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing.高血压患者不遵医嘱：如何制定并实施药物依从性检测。
Hypertension. 2022 Jan;79(1):12-23. doi: 10.1161/HYPERTENSIONAHA.121.17596. Epub 2021 Nov 5.
2
Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association.药物依从性与血压控制：美国心脏协会的科学声明。
Hypertension. 2022 Jan;79(1):e1-e14. doi: 10.1161/HYP.0000000000000203. Epub 2021 Oct 7.
3
Are SGLT2 Inhibitors New Hypertension Drugs?钠-葡萄糖协同转运蛋白2抑制剂是新型抗高血压药物吗？
Circulation. 2021 May 4;143(18):1750-1753. doi: 10.1161/CIRCULATIONAHA.121.053709. Epub 2021 May 3.
4
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.卡格列净对 2 型糖尿病和慢性肾脏病患者血压的影响及其对临床结局的影响：来自 CREDENCE 试验的观察。
Circulation. 2021 May 4;143(18):1735-1749. doi: 10.1161/CIRCULATIONAHA.120.048740. Epub 2021 Feb 8.
5
SGLT2 Inhibitors in Resistant Hypertension: A Sweet Solution.钠-葡萄糖协同转运蛋白2抑制剂用于顽固性高血压：一种有效的解决方案
Am J Hypertens. 2020 Dec 31;33(12):1071-1074. doi: 10.1093/ajh/hpaa100.
6
Hypertension Canada's 2020 Evidence Review and Guidelines for the Management of Resistant Hypertension.加拿大高血压协会 2020 年耐药性高血压证据综述和管理指南。
Can J Cardiol. 2020 May;36(5):625-634. doi: 10.1016/j.cjca.2020.02.083.
7
Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children.加拿大高血压学会 2020 年成人和儿童高血压预防、诊断、风险评估和治疗综合指南。
Can J Cardiol. 2020 May;36(5):596-624. doi: 10.1016/j.cjca.2020.02.086.
8
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.恩格列净治疗疑似耐药性高血压患者：来自 EMPA-REG OUTCOME 试验的事后分析。
Am J Hypertens. 2020 Dec 31;33(12):1092-1101. doi: 10.1093/ajh/hpaa073.
9
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
10
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.恩格列净在 2 型糖尿病合并高血压的黑人患者中的降血糖和降压作用。
Circulation. 2019 Apr 30;139(18):2098-2109. doi: 10.1161/CIRCULATIONAHA.118.036568.
Zotero 插件